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perceived differently according to the individuals questioned. The
minimum prevalence estimated of 3.2% in Germany corresponds
to 2.26 million of FM sufferers.
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OBJECTIVES: Fibromyalgia syndrome (FM) is an under diag-
nosed disorder of unknown etiology. The prevalence rate is
thought to be about 2% in the general population, 5.8% of
women ages 40–60 and as high as 8% in women ages 55–64.
Recent European estimates are needed. This aim of the study was
to estimate the prevalence of FM in the general adult population,
in France and describe the socio-demographic characteristics of
patients. METHODS: The French validated version of the
London Fibromyalgia Epidemiology Study Screening Question-
naire (4 items relating to widespread pain and 2 items on fatigue)
was administered to a representative community sample of 1014
subjects aged over 15 years, selected by the quota method. The
questionnaire was submitted to a sample of rheumatology out-
patients (n = 178), who were then examined by a trained rheu-
matologist to conﬁrm or exclude the diagnosis of FM according
to the 1990 American College of Rheumatology criteria. The
prevalence of FM in the general population was estimated by
applying the predictive positive value to eligible community sub-
jects (i.e., positive screens). RESULTS: In the community sample,
9.8% and 5.0% screened positive for widespread pain without
and with fatigue, respectively. Among rheumatology outpatients,
47.1% and 34.8% were screened positive respectively, whereas
10.6% were conﬁrmed FM cases. Based on widespread criteria,
the prevalence of FM was estimated at 2.2 % (95% CI: 1.3%–
3.1%) in the French general population. The corresponding
ﬁgure was 1.4 % (95% CI, 0.7%–2.1%) if pain is added. FM
sufferers are females with an average age of 47.3 years old (SD:
12.4, 21.5–68.0). CONCLUSIONS: Our ﬁndings are in agree-
ment with those of earlier national survey reports. A point preva-
lence of 1.4% would translate in approximately 680,000 patients
with FM in France.
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OBJECTIVES: To assess the estimated prevalence of ﬁbro-
myalgia syndrome (FM) among the adult population in
United-Kingdom in the general population, using the London
Fibromyalgia Epidemiology Study—Screening Questionnaire
(LFESSQ) and American College of Rheumatology (ACR) clas-
siﬁcation criteria. METHODS: The LFES-SQ was administered
to a representative community sample of 1500 subjects aged over
15 years, selected by the quota method. A positive screen was
deﬁned as: (1) meeting the 4-pain criteria alone (LFESSQ-4), or
meeting both the 4-pain and 2-fatigue criteria (LFESSQ-6). The
positive predictive value of LFESSQ-4 and LFESSQ-6, was esti-
mated in different European countries, this questionnaire was
submitted to a sample of rheumatology outpatients (n = 1.125),
who were then examined by a trained rheumatologist to conﬁrm
or exclude the diagnosis of FM according to the 1990 American
College of Rheumatology criteria. The prevalence of FM in the
English general population was estimated by applying the pre-
dictive positive value to eligible community subjects (i.e., positive
screens) in UK. RESULTS: The community sample is constituted
of 765 females and 735 men. 7.8% screened positive for
LFESSQ-4 (9.3% in females and 6.3% in males respectively). A
total of 4.3% screened positive for LFESSQ-6 (5.5% in females
and 3.0% in males respectively). Based on positive screens for
LFESSQ 4 items (pain only), the prevalence of FM would be
estimated at 2.8% (95% CI: [1.9–3.6] ; 3.3% in females and
2.2% in males respectively). The corresponding ﬁgure was 1.8 %
(95% CI: [1.1–2.5] ; 2.3% in females and 1.3 % in males
respectively) if positive screens for LFESSQ-6 (pain and fatigue)
were considered. CONCLUSIONS: Our study conﬁrms the
results of publications in Canada, US or Spain, with slightly
differences probably due to the different methodologies and
populations used. A point prevalence of 1.8 % would translate in
approximately 880 thousands of patients with FM in UK.
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OBJECTIVES: To assess the estimated prevalence of possible
ﬁbromyalgia (FM) sufferers among the adult population in Italy
using a screening questionnaire, the London Fibromyalgia
Epidemiology Study—Screening Questionnaire (LFESSQ).
METHODS: Every patients going to visit a rheumatologist at a
hospital in Firenze, during a 30-day period, what the reason of
their visit, were interviewed using the LFESSQ with two addi-
tional questions on fatigue, and examined to conﬁrm or exclude
the diagnostic of FM using American College of Rheumatology
(ACR) classiﬁcation criteria. The screening questionnaire was
also administered to a representative community sample more
than 15 years old, selected by the quota method. The prevalence
of FM was estimated in the general population, applying the
predictive positive value, observed in consultation, to the positive
screens. RESULTS: 31.3 % patients interviewed were found posi-
tive for chronic widespread pain, 20.7% for widespread pain and
fatigue and in 26.2% [25.6–26.7] the diagnosis of FM was
conﬁrmed. In the general adult population, 10.1% subject were
positive for widespread pain and 5.2% for widespread pain and
fatigue. The prevalence in general population, is 6.6% [5.1–8.1],
if patients screened positive for chronic widespread pain are
considered. If fatigue is added, the prevalence of 3.7% [2.6–4.8].
Prevalence rises with age until the age group 75–84 years old. FM
sufferers are 84% females and an average age of 52.9 years old
(SD: 14.2). CONCLUSIONS: Our study conﬁrms the results
from Canada, US or Spain, with slight differences probably due
to the different methodologies and populations employed. The
minimum prevalence estimated of 3.6% in Italy, these means that
approximately 1.8 millions of Italians, largely women, may suffer
from FM.
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OBJECTIVES: To estimate the prevalence of ﬁbromyalgia syn-
drome (FM) in rheumatology consultation and in the general
adult population, in Portugal. METHODS: All patients going to
visit the rheumatologist in the Hospital Egas Moniz and in Hos-
pital Santa Maria in Lisbon during a 30-days period, were inter-
viewed using the London Fibromyalgia Epidemiological Study
(LFES) Screening Questionnaire, with two additional questions
on fatigue, and examined to conﬁrm or exclude the diagnostic of
FM using American College of Rheumatology (ACR) classiﬁca-
tion criteria. The screening questionnaire validated in Portuguese
A538 Abstracts
